Abstract
Although isosorbide 5-mononitrate (IS-5-MN) has theoretical advantages over isosorbide dinitrate (ISDN) in terms of metabolism and bioavailability [1–3] there is no conclusive evidence to show that these are reflected in improved therapeutic benefit in clinical practice. A study has therefore been undertaken to compare the efficacy and acceptability of IS-5-MN, ISDN and the beta-adrenoreceptor antagonist propranolol (PROP) in the management of 20 patients with angina pectoris. This is an interim report.
This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Down WH, Chassaud LF, Grundy RK (1974) Biotransformation of isosorbide dinitrate in humans. J Pharm Sci 63: 1147–1149
Abshagen U, Sporl-Radnn S (1980) Pharmacokinetics and effect of 5-isosorbide mononitrate (5IS-5-MN) in normal man. In: World conference on clinical pharmacology and therapeutics. MacMillan, London, p.0377
Abshagen U, Betzien G, Endele R, Kaufmann B (1981) Pharmacokinetics of intravenous and oral isosorbine-5-mononitrate. Eur J Clin Pharmacol 20: 269–275
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1987 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Irvine, N.A., Maclean, D., McDevitt, D.G. (1987). Comparison of the Efficacy and Acceptability of Isosorbide 5-Mononitrate, Isosorbide Dinitrate and Propranolol in the Management of Angina Pectoris. In: Julian, D.G., Rittinghausen, R., Überbacher, H.J. (eds) Mononitrate II. International Boehringer Mannheim Symposia. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-72689-7_29
Download citation
DOI: https://doi.org/10.1007/978-3-642-72689-7_29
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-17832-3
Online ISBN: 978-3-642-72689-7
eBook Packages: Springer Book Archive